Tools
Tools
Webb, Eika, Rigby, Ishmeala, Michelen, Melina, Dagens, Andrew, Cheng, Vincent, Rojek, Amanda M, Dahmash, Dania, Khader, Susan, Gedela, Keerti, Norton, Alice, Cevik, Muge, Cai, Erhui, Harriss, Eli, Lipworth, Samuel, Nartowski, Robert, Groves, Helen, Hart, Peter, Blumberg, Lucille, Fletcher, Tom, Jacob, Shevin 
ORCID: https://orcid.org/0000-0003-2425-9394, Sigfrid, Louise and Horby, Peter W
(2022)
'Availability, scope and quality of monkeypox clinical management guidelines globally: a systematic review'. BMJ Global Health, Vol 7, Issue 8, e009838.
|
Text
1-s2.0-S2589537022004023-main.pdf - Published Version Available under License Creative Commons Attribution. Download (796kB) | Preview |
Abstract
Background: Monkeypox (MPX) is an important human orthopoxvirus infection. There has been an increase in MPX cases and outbreaks in endemic and non-endemic regions in recent decades. We appraised the availability, scope, quality, and inclusivity of clinical management guidelines for MPX globally.
Methods: For this systematic review, we searched six databases from inception until 14 Oct. 2021, augmented by a grey literature search until 17 May 2022. MPX guidelines providing treatment and supportive care recommendations were included, with no exclusions for language. Two reviewers assessed the guidelines. Quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool.
Results: Of 2026 records screened, 14 guidelines were included. Overall, most guidelines were of low-quality with a median score of 2 out of 7 (range: 1-7), lacked detail and covered a narrow range of topics. Most guidelines focused on adults, five (36%) provided some advice for children, three (21%) for pregnant women, and three (21%) for people living with HIV. Treatment guidance was mostly limited to advise on antivirals; seven guidelines advised cidofovir (four specified for severe MPX only); 29% (4/14) tecovirimat, and 7% (1/14) brincidofovir. Only one guideline provided recommendations on supportive care and treatment of complications. All guidelines recommended vaccination as post-exposure prophylaxis (PEP). Three guidelines advised on vaccinia immune globulin as PEP for severe cases in people with immunosuppression.
Conclusion: Our results highlight a lack of evidence-based clinical management guidelines for MPX globally. There is a clear and urgent need for research into treatment and prophylaxis including for different risk populations. The current outbreak provides an opportunity to accelerate this research through coordinated high-quality studies. New evidence should be incorporated into globally accessible guidelines, to benefit patient and epidemic outcomes. A ‘living guideline’ framework is recommended.
| Item Type: | Article |
|---|---|
| Subjects: | WA Public Health > WA 20.5 Research (General) WC Communicable Diseases > WC 20 Research (General) WC Communicable Diseases > Virus Diseases > Infectious Viral Skin Diseases > WC 584 Poxviridae infections |
| Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
| Digital Object Identifer (DOI): | https://doi.org/10.1136/bmjgh-2022-009838 |
| Depositing User: | Cathy Waldron |
| Date Deposited: | 05 Oct 2022 10:52 |
| Last Modified: | 05 Oct 2022 10:52 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/21252 |
Statistics
Actions (login required)
 |
Edit Item |